News|Articles|August 10, 2026

European Society of Cardiology 2026 Preview: 6 Trials to Know

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

The European Society of Cardiology (ESC) Congress 2026, set to begin on August 28, 2026, in Munich, Germany, will collect some of the biggest trials and most impactful news in cardiology over the last 12 months. From heart failure and stroke to cardiomyopathy and lipid-lowering, every headlining disease state will be addressed during this 3-day conference. Major potential treatments like aficamten and pacibekitug will prove their potential, while data from terminated trials like LIBREXIA ACS and CARDIO-TTRansform will provide valuable insights into future treatment strategies for underrepresented populations.

Related to this article

September 24th, 2026

Q&A: Clinician Investing and Injection Anxiety, With Manju Dawkins, MD

Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.

September 23rd, 2026

Conference Preview: 2026 EADV Congress in Vienna

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

September 22nd, 2026

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

September 21st, 2026

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

September 16th, 2026

Q&A: Berdazimer Gel and the Case Against 'Watch-and-Wait' for Molluscum

In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.

September 15th, 2026

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

September 24th, 2026

The Medical Sisterhood: Is Becoming a Doctor Still Worth It?

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.

September 24th, 2026

Anti-Alpha-Gal Antibodies Block IgE Binding in Alpha-Gal Syndrome

Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.